The results of this study, which show that GS can target STAT3 and HMGB1 and improve the effectiveness of BTZ, suggest the therapeutic relevance of this safe and affordable nutraceutical as a viable supplemental medicine for the treatment of MM. This evidence concerns the gene STAT3 and Miyoshi myopathy.